KRAS and colorectal carcinoma: As expected both, HT-29 as well as DLD-1 CRC cell lines exhibiting an activating BRAF or KRAS mutation, respectively, did not respond to the treatment with the EGFR inhibitor under 2D and lrECM 3D (Figure 6F and G).